Investor Relations

Tear Sheet

Company Profile

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. Our wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. 

Corporate

BioXcel Therapeutics
Erik Kopp
T: 203-494-7062
Ekopp@bioxceltherapeutics.com

Media

Transfer Agent

American Stock Transfer and Trust

Auditor

Ernst & Young LLP

Legal Counsel

Latham & Watkins LLP

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

SEC Filings

Filing date Form Description Filing Group
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
8-K

Report of unscheduled material events or corporate event

Current Reports
4/A

Amendment to a previously filed 4

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5

Data Provided by Refinitiv. Minimum 15 minutes delayed.